SC
Therapeutic Areas
Brii Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | COVID-19 | Approved |
| BRII-835 (VIR-2218) + BRII-179 (VBI-2601) | Chronic Hepatitis B | Phase 2 |
| BRII-179 (VBI-2601) | Chronic Hepatitis B | Phase 2a/2b |
| VIR-3434 | Chronic Hepatitis B | Preclinical/Phase 1 (ex-China) |
| BRII-732 | HIV (PrEP) | Phase 1 |
| BRII-296 | Postpartum Depression | Phase 1 |
Leadership Team at Brii Biosciences
ZH
Zhi Hong
Co-Founder, Chairman & CEO
ED
Eleanor de Groot
Chief Technology Officer
AS
Aleksandar Skuban
CNS Diseases Therapy Area Head
CS
Coy Stout
SVP, Head of U.S. Market Access & Patient Advocacy
KD
Karen D. Neuendorff
Chief People Officer & Head of HR
TY
Taiyin Yang
Board Director